Phagocytosis-inducing antibodies to Plasmodium falciparum upon immunization with a recombinant PfEMP1 NTS-DBL1α domain

Table 1 Properties of the antibodies used in the study

	Antibody type	ELISA-reactivity (ITvar60 NTS-DBL1α)	Surface reactivity (FCR3S1.2)	Rosette disruption (FCR3S1.2)	Opsonization for phagocytosis (FCR3S1.2)
mAbV2–3 (IgG2b)^a	IgG2b	+	+	+	−
mAbV2–6 (IgG2b)^a	IgG2b	+	+	+	−
mAbV2–14.1 (IgG2b)^a	IgG2b	+	+	+	−
mAbV2–14.2 (IgG2b)^a	IgG2b	+	+	+	−
mAbV2–4 (IgG2a)^a	IgG2a	+	+	−	+
mAbV2–7 (IgG2a)^a	IgG2a	+	+	+	+
mAbV2–13 (IgG2a)^a	IgG2a	+	+	+	+
mAbV2–16 (IgG2a)^a	IgG2a	+	+	−	+
mAbV2–17.1 (IgG2a)^a	IgG2a	+	+	+	+
mAbSly D^a	IgG2b	−	−	−	−
ITvar60 goat IgG^a	IgG	+	+	+	−
Control goat IgG^a	IgG	−	−	−	−
IM1	Serum	+	+	−	+
IM2	Serum	+	+	−	+
IM3	Serum	+	+	−	+
IM4	Serum	+	+	−	+
IM5	Serum	+	+	−	+
IM6	Serum	+	+	+	+
IMP	Serum	+	+	−	+
SCP	Serum	−	−	−	−

Table summarizes the sample name (mAb monoclonal antibody, IM immune malaria, IMP immune malaria pool, SCP Swedish control pool) and antibody type with their corresponding activity (±) in different assays. Positivity was determined based on the cut-off criteria specified in the “Methods” section
^aELISA reactivity, surface reactivity and rosette disruption activity for these antibodies have been published elsewhere [25] and are accordingly reported here

ISSN: 1475-2875